Table 1.

Demographic and biomarkers data from the study population

	n	Sex (f/m)	Age (years)	Duration (days)*	Plasma Nfl (pg/mL)		Plasma t-Tau (pg/mL)
					Mean + SD	95% CI	Mean + SD	95% CI
Controls
HC	70	22/48	64.7 ± 5.1	–	9.2 ± 3.4	8.4–10.0	2.5 ± 1.2	2.3–2.8
NND	26	13/13	64.1 ± 6.9	–	23.4 ± 39.6	7.4–39.5	3.7 ± 2.4	2.7–4.7
NND-Dem	17	9/8	63.2 ± 16.9	–	182.2 ± 151.5	104.3–260.1	3.1 ± 2.4	1.8–4.3
Neurodegenerative and vascular dementia
AD	44	26/18	68.5 ± 10.9	–	34.9 ± 33.4	24.7–45.8	3.6 ± 2.4	2.8–4.3
CJD	83	53/30	66.6 ± 8.8	273.4 ± 276.9	349.7 ± 505.4	239.4–460.1	45.1 ± 48.7	34.5–55.7
MM	51	36/16	66.8 ± 9.6	236.9 ± 213.7	384.5 ± 492.7	246.0–523.1	59.8 ± 54.4	44.6–75.1
MV	11	4/7	65.6 ± 7.1	316.3 ± 20.1	174.9 ± 118.4	95.3–254.4	23.7 ± 24.9	6.9–40.4
VV	18	11/7	68.9 ± 6.7	369.5 ± 417.3	395.1 ± 689.4	52.3–737.9	16.5 ± 19.3	6.9–26.2
DLB/PDD	35	11/24	69.8 ± 8.3	–	46.8 ± 37.1	33.8–59.7	2.3 ± 1.4	1.8–2.7
FTD	12	8/4	69.5 ± 7.2	–	27.8 ± 29.6	7.9–47.8	2.3 ± 1.3	1.4–3.1
VAD	22	15/5	70.0 ± 9.9	–	56.35 ± 51.7	33.4–79.3	3.2 ± 2.8	2.0–4.8

Number of cases studied, sex (number of female and male cases), age at onset (mean age with SD), and plasma Nfl and t-tau (mean concentrations with SD and 95% CI) are indicated. Information on disease duration (onset to death, mean days, SD) is only available for the CJD group. HC, healthy controls; NND, neurological diseases without dementia; NND-Dem, neurological diseases with dementia; AD, Alzheimer’s disease; CJD, Creutzfeldt-Jakob disease; MM/MV/VV, PRNP codon 129 methionine/valine polymorphism; DLB/PDD, dementia with Lewy bodies/Parkinson’s disease dementia; FTD, fronto-temporal dementia; VaD, vascular dementia; Nfl, neurofilament light; t-tau, total-tau. *Information on disease duration was available from 82 of 83 CJD cases